Lexington, United States
Orum Therapeutics is a public biotechnology company known for pioneering a novel class of protein degraders. As a key player in Biotechnology and Health Care, it has introduced TPD2®, a breakthrough in targeted protein degradation therapeutics described as degrader-antibody conjugates (DACs). These therapeutics uniquely combine the precision of antibodies with innovative degrader payloads to disrupt disease-causing proteins within cells.
The company’s lead programs, targeting GSPT1, along with advancements in next-generation payloads, aim to enhance the reach and effectiveness of DACs. Additionally, proprietary linker technologies are being developed to bolster future DAC programs' flexibility.
Founded in 2016 and headquartered in both Daejeon, South Korea, and Lexington, Massachusetts, U.S., Orum Therapeutics is strategically poised to deliver cutting-edge cancer therapies. Their last investment, a $54.00M Series B at 23 June 2021, involved investors like InterVest Co., KB Investments, and DS Asset Management among others.
Crossbow Therapeutics, Inc
